Table 2. Fold differences in sensitivity to small-molecule inhibitors, berberine and doxorubicin in MCF-7/pLXSN, MCF-7/NGAL and MCF-7/DoxR cells.1.
| Drug treatment | MCF-7/NGAL | MCF-7/DoxR |
|---|---|---|
| AG1478 (EGFR Inh) |
67 X↓ |
333 X↓ |
| ABT-737 (Bcl-2 Inh) |
1,000 X↓ |
667 X↓ |
| Rapamycin (mTORC1) |
1.3 X ↑ |
667 X↑ |
| KN-93 (CaM-K) |
9.2 X↓ |
23 X↑ |
| Berberine (AMPK, others) |
166 X↓ |
— |
| Doxorubicin (topoisomerase, others) |
1.3 X↓ |
25 X↑ |
| Dox + 250 nM AG1458 |
— |
6.7 X↑ |
| Dox + 50 nM ABT-737 |
2 X↑ |
1.1 X↑ |
| Dox + 5 nM Rapa |
47 X↑ |
1.7 X↑ |
| Dox + 250 nM KN-93 |
6 X↑ |
2.5 X↑ |
| Dox + 250 nM Berberine | 7 X↓ | 8.8 X↓ |
1Fold change in IC50s were normalized to the IC50s detected in MCF-7/pLXSN cells. ↓ indicates a decrease in IC50 in comparison to MCF-7/pLXSN control cells. ↑ indicates an increase in the IC50 compared with MCF-7/pLXSN control cells. Estimated data values obtained from drug titrations derived from graphs in Figures 1–5 and listed in Table 1.